Division of Medical Sciences & Graduate Entry Medicine, School of Medicine, Royal Derby Hospital, University of Nottingham, Derby, United Kingdom.
Department of Renal Medicine, Royal Derby Hospital, Derby, United Kingdom.
Front Endocrinol (Lausanne). 2020 Jun 10;11:369. doi: 10.3389/fendo.2020.00369. eCollection 2020.
Osteocalcin (OCN) is a bone-derived protein that is detected within human calcified vascular tissue. Calcification is particularly prevalent in chronic kidney disease (CKD) patients but the role of OCN in calcification, whether active or passive, has not been elucidated. Part 1: The relationship between OCN, CKD and vascular calcification was assessed in CKD patients ( = 28) and age-matched controls ( = 19). Part 2: , we analyzed whether addition of uncarboxylated osteocalcin (ucOCN) influenced the rate or extent of vascular smooth muscle cell (VSMC) calcification. Human aortic VSMCs were cultured in control media or mineralisation inducing media (MM) containing increased phosphate with or without ucOCN (10 or 30 ng/mL) for up to 21 days. Markers of osteogenic differentiation and calcification were determined [alkaline phosphatase (ALP) activity, total intracellular OCN, Runx2 expression, α-SMA expression, alizarin red calcium staining, and calcium quantification]. Part 1 results: In our human population, calcification was present (mean age 76 years), but no differences were detected between CKD patients and controls. Plasma total OCN was increased in CKD patients compared to controls (14 vs. 9 ng/mL; < 0.05) and correlated to estimated glomerular filtration rate ( < 0.05), however no relationship was detected between total OCN and calcification. Part 2 results: , ALP activity, α-SMA expression and calcium concentrations were significantly increased in MM treated VSMCs at day 21, but no effect of ucOCN was observed. Cells treated with control media+ucOCN for 21 days did not show increases in ALP activity nor calcification. In summary, although plasma total OCN was increased in CKD patients, this study did not find a relationship between OCN and calcification in CKD and non-CKD patients, and found no evidence of an active role of ucOCN in vascular calcification as assessed over 21 days. ucOCN appears not to be a mediator of vascular calcification, but further investigation is warranted.
骨钙素 (OCN) 是一种在人类钙化血管组织中检测到的骨源性蛋白。钙化在慢性肾脏病 (CKD) 患者中尤为普遍,但 OCN 在钙化中的作用(无论是主动还是被动)尚未阐明。第 1 部分:在 CKD 患者(=28 例)和年龄匹配的对照组(=19 例)中评估了 OCN、CKD 和血管钙化之间的关系。第 2 部分:我们分析了未羧化骨钙素 (ucOCN) 的添加是否会影响血管平滑肌细胞 (VSMC) 钙化的速度或程度。将人主动脉 VSMC 在对照培养基或含有增加磷酸盐的矿化诱导培养基 (MM) 中培养,用或不用 ucOCN(10 或 30ng/ml)培养长达 21 天。测定成骨分化和钙化的标志物[碱性磷酸酶 (ALP) 活性、细胞内总 OCN、Runx2 表达、α-SMA 表达、茜素红钙染色和钙定量]。第 1 部分结果:在我们的人群中,存在钙化(平均年龄 76 岁),但 CKD 患者和对照组之间没有差异。与对照组相比,CKD 患者的血浆总 OCN 增加(14 对 9ng/ml;<0.05),并与估计肾小球滤过率相关(<0.05),但总 OCN 与钙化之间未检测到关系。第 2 部分结果:在 MM 处理的 VSMC 中,第 21 天 ALP 活性、α-SMA 表达和钙浓度显著增加,但未观察到 ucOCN 的作用。用对照培养基+ucOCN 处理 21 天的细胞中,ALP 活性和钙化均未增加。总之,尽管 CKD 患者的血浆总 OCN 增加,但本研究未发现 CKD 和非 CKD 患者的 OCN 与钙化之间存在关系,并且在 21 天内没有发现 ucOCN 在血管钙化中的积极作用的证据。ucOCN 似乎不是血管钙化的介质,但需要进一步研究。